已收录 268921 条政策
 政策提纲
  • 暂无提纲
CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
[摘要] Despite advances in the understanding of the genetic landscape of acute myeloid leukemia (AML) and the addition of targeted biological and epigenetic therapies to the available armamentarium, achieving long-term disease-free survival remains an unmet need. Building on growing knowledge of the interactions between leukemic cells and their bone marrow microenvironment, strategies to battle AML by immunotherapy are under investigation. In the current review we describe the advances in immunotherapy for AML, with a focus on chimeric antigen receptor (CAR) T cell therapy. CARs constitute powerful immunologic modalities, with proven clinical success in B-Cell malignancies. We discuss the challenges and possible solutions for CAR T cell therapy development in AML, and examine the path currently being paved by preclinical and clinical efforts, from autologous to allogeneic products.
[发布日期] 2022-01-10 [发布机构] 
[效力级别]  [学科分类] 
[关键词] immune effector cell therapy;acute myeloid leukemia;cancer immunotherapy;chimeric antigen receptor T cells;allogeneic [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文